AstraZeneca Pharmaceuticals LP
NEWS
With the holidays around the corner and people expected to gather, public health officials have expressed concerns over a possible increase in COVID-19 cases, particularly with the highly infectious Omicron variant on the rise.
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
A study out of the University of Oxford found that two shots of the Pfizer-BioNTech vaccine or the AstraZeneca-Oxford vaccine were not as effective at against Omicron as they were against previous variants.
The FDA has approved emergency use authorization for AstraZeneca’s Evusheld cocktail as prophylaxis against COVID-19 infection in adults and adolescents aged at least 12 years.
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
JOBS
IN THE PRESS